Type 2 Diabetes Drugs Fail to Improve the Most Serious Long-Term Complications
[hide all summaries]
(February 2010)
The article discusses why all of these 16 diabetes drugs carry a label stating: "There have been no clinical studies establishing conclusive evidence of macrovascular risk reduction [heart attacks, strokes, etc] with oral antidiabetic drug[s]." The article also explains why lifestlyle changes such as diet and exercise to prevent or even treat type II diabetes are not heavily promoted or usually reimbursed.

A Review of Exenatide (BYETTA) for Type-2 Diabetes
[hide all summaries]
(November 2009)
Because exenatide (BYETTA) is a new drug with increasing reports of severe, hospitalization-requiring pancreatitis and offers no significant breakthrough compared to other diabetes drugs, we urge readers not to use it until 2012--seven years after its approval, by which time much more will be known about its dangers.